vimarsana.com

Page 119 - ஸ்டான்போர்ட் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How to safely sleep in headphones - The Washington Post

Affibody and Inmagene autoimmune partnership completes regulatory milestone

Affibody and Inmagene autoimmune partnership completes regulatory milestone Affibody and Inmagene Biopharmaceuticals report that the US FDA has cleared the interleukin-17 (IL-17) blocker, izokibep, to proceed to phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis. Uveitis is an orphan disease with significant unmet medical need. It is an inflammation of the uveal tract but can also include the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. It is one of the leading causes of blindness worldwide. Sweden’s Affibody and Inmagene, which has wholly owned subsidiaries in San Diego, Shanghai, and Hangzhou, are jointly developing izokibep, a novel bispecific agent, targeting both subunits of IL-17A as well as albumin, to treat multiple autoimmune diseases.

Live Webinar: Wearable Technologies for Detecting Pre-Symptomatic Illness and Infections

Coronavirus deranges the immune system in complex and deadly ways

There s a reason soldiers go through basic training before heading into combat: Without careful instruction, green recruits armed with powerful weapons could be as dangerous to one another as to the enemy. The immune system works much the same way. Immune cells, which protect the body from infections, need to be educated to recognize bad guys and to hold their fire around civilians. Advertisement: In some covid patients, this education may be cut short. Scientists say unprepared immune cells appear to be responding to the coronavirus with a devastating release of chemicals, inflicting damage that may endure long after the threat has been eliminated.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.